Medpace Holdings, Inc.
8-K on 05/21/2020   Download
SEC Document
SEC Filing
false 0001668397 0001668397 2020-05-15 2020-05-15

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 15, 2020

 

MEDPACE HOLDINGS, INC.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

 

001-37856

 

32-0434904

(State or Other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

5375 Medpace Way

Cincinnati, Ohio 45227

(Address of Principal Executive Offices, and Zip Code)

(513) 579-9911

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock

 

MEDP

 

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 


Item 5.07. Submission of Matters to a Vote of Security Holders.

  (a) On May 15, 2020, Medpace Holdings, Inc. (the “Company”) held its 2020 Annual Meeting of Stockholders.

  (b) Stockholders voted on the matters set forth below.

Proposal 1 — Election of Directors

The following nominees were elected to the Company’s Board of Directors to serve as Class I Directors until the Company’s 2023 Annual Meeting of Stockholders based upon the following votes:

 

Votes
For

   

Votes
Withheld

   

Broker
Non-Votes

 

Brian T. Carley

   

20,003,616

     

11,971,146

     

1,275,641

 

Thomas C. King

   

31,778,293

     

196,469

     

1,275,641

 

Robert O. Kraft

   

19,900,547

     

12,074,215

     

1,275,641

 

Proposal 2 — Ratification of Appointment of Independent Registered Public Accounting Firm

The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2020 was ratified based upon the following votes:

Votes
For

 

Votes
Against

   

Votes
Abstained

   

Broker
Non-Votes

 

33,084,140

   

154,417

     

11,846

     

0

 

Proposal 3 — Advisory Vote on the Compensation of our Named Executive Officers

The proposal to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers was not approved based upon the following votes:

Votes
For

 

Votes
Against

   

Votes
Abstained

   

Broker
Non-Votes

 

10,493,264

   

21,455,484

     

26,014

     

1,275,641

 

Proposal 4 — Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of our Named Executive Officers

The proposal on the frequency of future advisory votes on the compensation of the Company’s Named Executive Officers received the following votes:

Votes For

One Year

 

Votes For

Two Years

   

Votes For

Three Years

   

Votes

Abstained

 

31,281,283

   

6,429

     

671,923

     

15,127

 

(c) Not applicable.

(d) Based upon the results set forth in item (b) (Proposal 4) above, and consistent with the Board’s recommendation, the Board of Directors has determined that advisory votes on executive compensation will be submitted to stockholders on an annual basis until the next required vote on the frequency of such votes.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

MEDPACE HOLDINGS, INC.

             

Date: May 21, 2020

 

 

By:

 

/s/ Stephen P. Ewald

 

 

Name:

 

Stephen P. Ewald

 

 

Title:

 

General Counsel and Corporate Secretary